Business Description
St Pharm Co Ltd
SIC : 2834
ISIN : KR7237690003
Total Employee Number:
704Compare
Compare
Traded in other countries / regions
237690.Korea Index Membership
KOSDAQ Composite Index IPO Date
2016-06-23Description
St Pharm Co Ltd is a South Korean contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. The company produces active pharmaceutical ingredients (APIs) and intermediates for both generic and new drug applications, operating under current Good Manufacturing Practice (cGMP) standards. Its business spans small molecule APIs, including anticancer and anticoagulant compounds, as well as oligonucleotide therapeutics, where it provides development and manufacturing services for RNA-based drugs. St Pharm also maintains a fine chemicals business. Its customers include pharmaceutical companies and drug developers in South Korea and internationally, particularly in the United States, Europe, and Asia. Revenue is generated primarily through custom manufacturing and development contracts, along with API supply agreements and licensing or technology transfer arrangements related to its oligonucleotide platform. The company is headquartered in South Korea and continues to expand its CDMO capacity for both small molecule and oligonucleotide production.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.28 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 0.67 | |||||
Interest Coverage | 58.74 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 6.66 | |||||
Beneish M-Score | -2.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.9 | |||||
3-Year EBITDA Growth Rate | 29 | |||||
3-Year EPS without NRI Growth Rate | 32.8 | |||||
3-Year FCF Growth Rate | 17 | |||||
3-Year Book Growth Rate | 16.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.61 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 22.84 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.21 | |||||
9-Day RSI | 42.6 | |||||
14-Day RSI | 41.99 | |||||
3-1 Month Momentum % | -21.02 | |||||
6-1 Month Momentum % | -35.62 | |||||
12-1 Month Momentum % | 10.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.28 | |||||
Quick Ratio | 1.28 | |||||
Cash Ratio | 0.87 | |||||
Days Inventory | 283.47 | |||||
Days Sales Outstanding | 54.44 | |||||
Days Payable | 25.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.54 | |||||
Dividend Payout Ratio | 0.13 | |||||
Forward Dividend Yield % | 0.54 | |||||
5-Year Yield-on-Cost % | 0.54 | |||||
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 2.37 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.15 | |||||
Operating Margin % | 18.33 | |||||
Net Margin % | 19.87 | |||||
EBITDA Margin % | 29.1 | |||||
FCF Margin % | 20.58 | |||||
OCF Margin % | 29.72 | |||||
ROE % | 13.28 | |||||
ROA % | 9.68 | |||||
ROIC % | 9.98 | |||||
3-Year ROIIC % | 20.86 | |||||
ROC (Joel Greenblatt) % | 15.45 | |||||
ROCE % | 12.81 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.84 | |||||
Forward PE Ratio | 21.59 | |||||
PE Ratio without NRI | 24.84 | |||||
Shiller PE Ratio | 85.55 | |||||
Price-to-Owner-Earnings | 30.68 | |||||
PS Ratio | 4.91 | |||||
PB Ratio | 3.07 | |||||
Price-to-Tangible-Book | 3.16 | |||||
Price-to-Free-Cash-Flow | 25.5 | |||||
Price-to-Operating-Cash-Flow | 17.3 | |||||
EV-to-EBIT | 23.39 | |||||
EV-to-EBITDA | 16.36 | |||||
EV-to-Revenue | 4.75 | |||||
EV-to-FCF | 23.08 | |||||
Price-to-GF-Value | 0.79 | |||||
Price-to-Projected-FCF | 6.84 | |||||
Price-to-Median-PS-Value | 0.82 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.99 | |||||
Price-to-Graham-Number | 1.87 | |||||
| Price-to-Net-Current-Asset-Value | 8.45 | |||||
Earnings Yield (Greenblatt) % | 4.26 | |||||
FCF Yield % | 3.99 | |||||
Forward Rate of Return (Yacktman) % | 19.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
St Pharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 386,456.102 | ||
| EPS (TTM) (â‚©) | 3699.856 | ||
| Beta | 0.3868 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.6 | ||
| Volatility % | 58.84 | ||
| 14-Day RSI | 41.99 | ||
| 14-Day ATR (â‚©) | 5210.161876 | ||
| 20-Day SMA (â‚©) | 98365 | ||
| 12-1 Month Momentum % | 10.83 | ||
| 52-Week Range (â‚©) | 84100 - 172100 | ||
| Shares Outstanding (Mil) | 20.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
St Pharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
St Pharm Co Ltd Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| KRW 500.000000 Cash Dividend | 2026-03-30 | 159,300.00 (+4.46%) | ||
| KRW 500.000000 Cash Dividend | 2024-12-27 | 87,000.00 (+1.05%) |
Show
Entries
St Pharm Co Ltd Frequently Asked Questions
What is St Pharm Co Ltd(XKRX:237690)'s stock price today?
The current price of XKRX:237690 is â‚©91000.00. The 52 week high of XKRX:237690 is â‚©172100.00 and 52 week low is â‚©84100.00.
When is next earnings date of St Pharm Co Ltd(XKRX:237690)?
The next earnings date of St Pharm Co Ltd(XKRX:237690) is .
Does St Pharm Co Ltd(XKRX:237690) pay dividends? If so, how much?
The Dividend Yield %  of St Pharm Co Ltd(XKRX:237690) is 0.54% (As of Today), Highest Dividend Payout Ratio of St Pharm Co Ltd(XKRX:237690) was 1.57. The lowest was 0.13. And the median was 0.37. The  Forward Dividend Yield % of St Pharm Co Ltd(XKRX:237690) is 0.54%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers